Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Koarada, S.
Right arrow Articles by Nagasawa, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Koarada, S.
Right arrow Articles by Nagasawa, K.
Related Collections
Right arrow Systemic Lupus Erythematosus and Autoimmunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2001; 40: 1315-1316
© 2001 British Society for Rheumatology

Letters to the Editor

CD180 (RP105) in rheumatic diseases

S. Koarada, Y. Tada, Y. Kikuchi, O. Ushiyama, N. Suzuki, A. Ohta1 and K. Nagasawa

Department of Internal Medicine, Saga Medical School, Nabeshima 5-1-1, Saga and
1 Clinical Nursing, Saga Medical School, Saga, Japan 849-8501

SIR, CD180 (RP105) is a leucine-rich repeat (LRR) molecule expressed on the membrane of B-cells [1, 2]. The molecules bearing LRRs control the recognition of pathogens and the subsequent activation of the immune system [3, 4]. CD180 belongs to the toll-like receptor family of pathogen receptors. CD180 takes part in B-cell recognition and lipopolysaccharide signalling [5].

Recent studies have shown decreased CD180 expression on B-cells in systemic lupus erythematosus . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?